Clinical Trials Logo

X-linked Agammaglobulinaemia clinical trials

View clinical trials related to X-linked Agammaglobulinaemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01963143 Completed - Clinical trials for Common Variable Immunodeficiency

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

GMX07
Start date: February 2014
Phase: Phase 3
Study type: Interventional

The primary objective is to demonstrate the bioequivalence of Gammaplex® 10 intravenous immunoglobulin (IGIV) and Gammaplex® 5% IGIV with respect to area under the curve within a 28-day dosing interval (AUC0-28) in a cohort of adult subjects. The secondary objectives are to demonstrate the bioequivalence of Gammaplex® 10 IGIV and Gammaplex® 5% IGIV with respect to area under the curve within a 21-day dosing interval (AUC0-21) in adult subjects; to assess the pharmacokinetics of Gammaplex 10 IGIV and Gammaplex 5% IGIV including Immunoglobulin G (IgG) trough levels and to investigate the safety and tolerability of Gammaplex 10 IGIV and Gammaplex 5% IGIV in adults subjects; to assess the pharmacokinetics of Gammaplex 10 IGIV including IgG trough levels and to investigate the safety and tolerability of Gammaplex 10 IGIV in pediatric subjects.

NCT ID: NCT01884311 Completed - Clinical trials for Common Variable Immunodeficiency

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

SCIG03
Start date: August 20, 2015
Phase: Phase 3
Study type: Interventional

The main objective of the study is to determine the pharmacokinetics profile of Subgam-VF. The secondary objectives are to assess the safety of Subgam-VF and refine the dose adjustment coefficient for Subgam-VF needed for subjects switching from prior intravenous immunoglobulin (IGIV) therapy.